#AS­CO17: Epizyme will hunt a quick OK for tazeme­to­stat, de­spite dis­ap­point­ing an­a­lysts with new da­ta

As the dust be­gan to set­tle from the AS­CO ab­stract drop last night, sev­er­al an­a­lysts weighed in not­ing their cau­tious lack of op­ti­mism for Epizyme’s lat­est look at the da­ta for tazeme­to­stat, its EZH2 in­hibitor now in Phase II for ep­ithe­lioid sar­co­ma.

RBC’s Matthew Eck­ler not­ed the lat­est da­ta were “be­low our ex­pec­ta­tions.”

For Ge­of­frey Porges at Leerink: “These re­sults squeaked over the tri­al’s hur­dle for pro­ceed­ing to co­hort ex­pan­sion and the 13% ORR is be­low our men­tal thresh­old of a 20-30% re­sponse rate.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.